Transcranial Direct Current Stimulation (tDCS) for the Treatment of Tinnitus
Launched by CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS · Apr 10, 2012
Trial Information
Current as of May 07, 2025
Unknown status
Keywords
ClinConnect Summary
Subjective tinnitus is a distressing condition characterized by the sensation of sound or noise in the absence of internal or external stimuli. Research indicates that tinnitus may develop due to maladaptive plastic changes in the auditory cortex and limbic system. These changes can be targeted using safe and noninvasive brain stimulation techniques like transcranial direct current stimulation (tDCS). TDCS alters the excitability of the cortex using a weak direct current and may lead to long-term plastic changes, making it a potential therapeutic tool for the treatment of tinnitus.
Transie...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age of at least 18 years
- • Chronic tinnitus for at least 1 year
- • Diagnosis of chronic subjective non-pulsatile tinnitus
- • Age-adjusted normal (sensorineural) hearing
- • Score of 25 or above on the Mini-mental state examination (MMSE)
- • Must comply with use of contraceptives during interventions
- Exclusion Criteria:
- • Objective tinnitus
- • Concurrent treatment for tinnitus
- • Prior exposure to transcranial direct current stimulation (tDCS)
- • Electronic implants or metallic objects in body, including cardiac pacemakers, cochlear implants, implanted medical pump, metal plate in skull, metal implant in the skull or eyes (other than dental appliances or fillings)
- • Skin conditions where electrodes will be applied
- • Major neurological co-morbidities
- • History of epilepsy and/or seizures
- • Pregnancy and/or lactation
About Centre Hospitalier Universitaire Vaudois
The Centre Hospitalier Universitaire Vaudois (CHUV) is a leading academic medical center located in Lausanne, Switzerland, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, CHUV plays a pivotal role in translating scientific discoveries into transformative therapies, enhancing patient care across a diverse range of medical disciplines. With a multidisciplinary team of experts and state-of-the-art facilities, CHUV is dedicated to fostering collaboration and delivering high-quality evidence that informs clinical practice and policy.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lausanne, Vaud, Switzerland
Patients applied
Trial Officials
David Benninger, MD
Principal Investigator
Centre Hospitalier Universitaire Vaudois
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials